Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifaximin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 4/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | NPY1R | P25929 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | BDKRB2 | P30411 | 2/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifaximin SCHEMBL124066 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL16229249 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL874028 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL14677545 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL13897021 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL23314507 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL9397878 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL17930616 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL124067 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL11956496 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725466-B2 | Rifaximin derivative and uses thereof | Salix Pharmaceuticals, Ltd (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160257700-A1 | RIFAXIMIN DERIVATIVE AND USES THEREOF | BAUSCH HEALTH US, LLC | 2016-09-08 | — | — | US | disclosed |
| US-9364467-B2 | Rifaximin derivative and uses thereof | SALIX PHARMACEUTICALS, LTD. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9364467-B2 | Rifaximin derivative and uses thereof | SALIX PHARMACEUTICALS, LTD. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150342934-A1 | RIFAXIMIN DERIVATIVE AND USES THEREOF | ORAPHARMA, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150342934-A1 | RIFAXIMIN DERIVATIVE AND USES THEREOF | ORAPHARMA, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9035046-B2 | Rifaximin derivative and uses thereof | SALIX PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035046-B2 | Rifaximin derivative and uses thereof | SALIX PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140378495-A1 | RIFAXIMIN DERIVATIVE AND USES THEREOF | BAUSCH HEALTH AMERICAS, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140378495-A1 | RIFAXIMIN DERIVATIVE AND USES THEREOF | BAUSCH HEALTH AMERICAS, INC. | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342934-A1 | RIFAXIMIN DERIVATIVE AND USES THEREOF | CUTA, SSB, MRPL21 | ABCB11 248/4885ABCC4 3860/4885ABCC2 3530/4885 |
| US-20140378495-A1 | RIFAXIMIN DERIVATIVE AND USES THEREOF | CUTA, SSB, MRPL21 | ABCB11 248/4885ABCC4 3860/4885ABCC2 3530/4885 |
| US-20160257700-A1 | RIFAXIMIN DERIVATIVE AND USES THEREOF | CUTA, SSB, MRPL21 | ABCB11 248/4885ABCC4 3860/4885ABCC2 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.